Advertisement
Canada markets open in 5 hours 4 minutes

  • S&P/TSX

    21,885.38
    +11.66 (+0.05%)
     

  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     

  • DOW

    38,085.80
    -375.12 (-0.98%)
     

  • CAD/USD

    0.7331
    +0.0007 (+0.10%)
     

  • CRUDE OIL

    83.86
    +0.29 (+0.35%)
     

  • Bitcoin CAD

    87,827.66
    +455.09 (+0.52%)
     

  • CMC Crypto 200

    1,389.83
    -6.71 (-0.48%)
     

  • GOLD FUTURES

    2,358.30
    +15.80 (+0.67%)
     

  • RUSSELL 2000

    1,981.12
    -14.31 (-0.72%)
     

  • 10-Yr Bond

    4.7060
    +0.0540 (+1.16%)
     

  • NASDAQ futures

    17,757.00
    +189.50 (+1.08%)
     

  • VOLATILITY

    15.53
    +0.16 (+1.04%)
     

  • FTSE

    8,119.07
    +40.21 (+0.50%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • CAD/EUR

    0.6820
    -0.0001 (-0.01%)
     

SPPI ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of November 1, 2021 in the Class Action Filed on Behalf of Spectrum Pharmaceuticals, Inc. Limited Shareholders

Newsfile Corp.
·2 min read

New York, New York--(Newsfile Corp. - September 24, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) alleging that the Company violated federal securities laws.

Class Period: December 27, 2018 and August 5, 2021
Lead Plaintiff Deadline: November 1, 2021
No obligation or cost to you.

Learn more about your recoverable losses in SPPI:
https://www.kleinstocklaw.com/pslra-1/spectrum-pharmaceuticals-inc-loss-submission-form?id=19862&from=5

Spectrum Pharmaceuticals, Inc. NEWS - SPPI NEWS

CLASS ACTION CASE DETAILS: The filed complaint alleges that Spectrum Pharmaceuticals, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) the manufacturing facility for ROLONTIS, an investigational granulocyte-colony stimulating factor analog, maintained deficient controls and/or procedures; (ii) the foregoing deficiencies decreased the likelihood that the Food and Drug Administration would approve the ROLONTIS biologics license application ("BLA") in its current form; (iii) Spectrum had therefore materially overstated the ROLONTIS BLA's approval prospects; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

ADVERTISEMENT

WHAT THIS MEANS TO YOU AS A SHAREHOLDER: If you have suffered a loss in Spectrum you have until November 1, 2021 to petition the court for lead plaintiff status. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

NO COST TO YOU: If you purchased Spectrum securities during the relevant period, you may be entitled to compensation without payment of any out-of-pocket fees.

HOW TO PROTECT YOUR FINANCIAL INTERESTS: For additional information about the SPPI lawsuit, please contact J. Klein, Esq. by telephone at 212-616-4899 or click this link.

ABOUT KLEIN LAW FIRM
J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. The Klein Law Firm is a boutique litigation firm with experience in a wide range of areas including securities law, corporate finance and commercial litigation. Since 2011, our experienced attorneys have achieved superior results for our clients with a personalized focus. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/97629